IceCure Medical's ProSense Featured in Breast Cancer Studies
Ticker: ICCM · Form: 6-K · Filed: Dec 10, 2025 · CIK: 1584371
Sentiment: neutral
Topics: medical-device, clinical-studies, press-release
TL;DR
IceCure's ProSense cryoablation tech in 4 breast cancer studies at RSA 2025.
AI Summary
On December 10, 2025, IceCure Medical Ltd. announced that its ProSense® Cryoablation technology was featured in four independent breast cancer studies presented at the Radiological Society of America 2025 Annual Meeting. The company, headquartered in Caesarea, Israel, filed this report as a foreign private issuer.
Why It Matters
The inclusion of IceCure's technology in multiple studies at a major radiology conference highlights its potential role in breast cancer treatment and could influence future clinical adoption.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain new financial or operational information that would significantly alter the company's risk profile.
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report
- ProSense® (product) — Featured cryoablation technology
- Radiological Society of America 2025 Annual Meeting (event) — Conference where studies were presented
- December 10, 2025 (date) — Date of press release issuance
FAQ
What is the primary focus of the press release filed by IceCure Medical Ltd. on December 10, 2025?
The press release focuses on IceCure's ProSense® Cryoablation technology being featured in four independent breast cancer studies presented at the Radiological Society of America 2025 Annual Meeting.
What is the name of the technology highlighted in the studies?
The technology highlighted is IceCure's ProSense® Cryoablation.
Where were the studies featuring ProSense® presented?
The studies were presented at the Radiological Society of America 2025 Annual Meeting.
What type of report is this filing?
This filing is a Form 6-K, a Report of Foreign Private Issuer.
What is the principal executive office address of IceCure Medical Ltd.?
The principal executive office is located at 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel.
Filing Stats: 316 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2025-12-10 08:45:15
Filing Documents
- ea0269128-6k_icecure.htm (6-K) — 11KB
- ea026912801ex99-1_icecure.htm (EX-99.1) — 23KB
- 0001213900-25-119872.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: December 10, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2